Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cardio

Date Submitted: Jan 8, 2025
Date Accepted: Apr 1, 2025

The final, peer-reviewed published version of this preprint can be found here:

The rs243865 Polymorphism in Matrix Metalloproteinase-2 and its Association With Target Organ Damage in Patients With Resistant Hypertension: Cross-Sectional Study

Huynh A, Anh Hoang V, Anh Hoang T, Viet Tran A

The rs243865 Polymorphism in Matrix Metalloproteinase-2 and its Association With Target Organ Damage in Patients With Resistant Hypertension: Cross-Sectional Study

JMIR Cardio 2025;9:e71016

DOI: 10.2196/71016

PMID: 40311090

PMCID: 12061201

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The rs243865 Polymorphism In Matrix Metalloproteinase 2 And Its Association With Target Organ Damage In Resistant Hypertension Patients

  • An Huynh; 
  • Vu Anh Hoang; 
  • Tien Anh Hoang; 
  • An Viet Tran

ABSTRACT

Background:

Resistant hypertension presents significant clinical challenges, often precipitating a spectrum of cardiovascular complications. Particular attention recently has focused on the role of Matrix metalloproteinase-2 (MMP-2) gene polymorphisms, implicated in hypertensive target organ damage. Despite growing interest, the specific contribution of MMP-2 polymorphisms to such damage in resistant hypertension remains inadequately defined.

Objective:

This study is the first to examine the rs243865 (-1306C>T) polymorphism in the MMP-2 gene in the Vietnamese population and in patients with resistant hypertension (RH), underscoring its critical role as a genetic determinant of target organ damage (TOD).

Methods:

A cross-sectional study with both descriptive and analytical components, in 78 patients with resistant hypertension at the Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital from July 2023 to February 2024.

Results:

More than three-quarters of RH patients had carotid-femoral PWV >10 m/s and microalbuminuria at prevalence of 79.5% and 75.6%, respectively. And more than half of RH patients had LVMI, relative wall thickness and carotid artery stenosis with the prevalence of 56.4%, 55.1% and 52.6%, respectively. Of 78 studied resistent hypertension patients, the presence of genotype CC was 76.9%, genotype CT accounted for 20.5% and 2.6% of genotype TT. The percentage of SNP rs243865(-1306C>T) carring allele T was 23.1%. The MMP-2 gene polymorphism 1306C/T (rs243865) was significantly associated with EF and carotid artery stenosis with OR (95%CI) of 8.1(1.3-51.4); p=0.026 and 4.5(1.1-20.1); p=0.048 respectively. The allele T was found to be significantly associated with arterial stiffness including Brachial-ankle PWV and Carotid-Femoral PWV with the correlation coefficient (95%CI) of 2.2 (0.6-3.8) and 1.8 (0.5-3.2) respectively.

Conclusions:

The MMP-2 gene polymorphism rs243865 (-1306C>T) may have an association with measurable target organ damage in resistant hypertension.


 Citation

Please cite as:

Huynh A, Anh Hoang V, Anh Hoang T, Viet Tran A

The rs243865 Polymorphism in Matrix Metalloproteinase-2 and its Association With Target Organ Damage in Patients With Resistant Hypertension: Cross-Sectional Study

JMIR Cardio 2025;9:e71016

DOI: 10.2196/71016

PMID: 40311090

PMCID: 12061201

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.